| scholarly article | Q13442814 |
| P2093 | author name string | D F Brophy | |
| Y Lou | |||
| B M Sadler | |||
| C Gillotin | |||
| R E Polk | |||
| A Pastor | |||
| D S Israel | |||
| G E Chittick | |||
| W T Symonds | |||
| P2860 | cites work | CYP3A4 and the erythromycin breath test | Q47722007 |
| Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions | Q47900779 | ||
| Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor | Q48123921 | ||
| The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. | Q50867766 | ||
| Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. | Q52553124 | ||
| In vitro metabolism of a potent HIV-protease inhibitor (141W94) using rat, monkey and human liver S9. | Q53994978 | ||
| Amprenavir. | Q54135838 | ||
| Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycin | Q68055794 | ||
| Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial | Q70502398 | ||
| 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA) | Q73025618 | ||
| Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test | Q73369035 | ||
| Molecular and physical mechanisms of first-pass extraction | Q77939183 | ||
| Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. | Q33539266 | ||
| Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers | Q33700538 | ||
| Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. | Q33977160 | ||
| Noninvasive tests of CYP3A enzymes | Q34059919 | ||
| The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors | Q34065800 | ||
| Pharmacokinetic interaction between ritonavir and clarithromycin | Q34754557 | ||
| Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. | Q35134071 | ||
| Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients | Q37882764 | ||
| In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents | Q38507949 | ||
| Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein | Q41018603 | ||
| HIV-protease inhibitors | Q41751665 | ||
| Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. | Q44866694 | ||
| Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir | Q45756159 | ||
| Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells | Q46050952 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | clarithromycin | Q118551 |
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 978-984 | |
| P577 | publication date | 2000-04-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers | |
| P478 | volume | 44 |
| Q34127433 | Amprenavir: a review of its clinical potential in patients with HIV infection |
| Q47985538 | Clarithromycin, a cytochrome P450 inhibitor, can reverse mefloquine resistance in Plasmodium yoelii nigeriensis- infected Swiss mice |
| Q34509359 | Clinical pharmacology and pharmacokinetics of amprenavir. |
| Q46840679 | Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers |
| Q35072074 | Drug interactions between antiretroviral drugs and comedicated agents |
| Q33801821 | Drug interactions with new and investigational antiretrovirals |
| Q34053781 | Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease |
| Q39062284 | Effect of clarithromycin and fluconazole on the pharmacokinetics of montelukast in human volunteers. |
| Q36580598 | Emerging drugs to replace current leaders in first-line therapy for breast cancer |
| Q36399718 | Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug |
| Q36839698 | Fosamprenavir calcium plus ritonavir for HIV infection |
| Q37783447 | Impact of ATP-binding cassette transporters on human immunodeficiency virus therapy |
| Q34600493 | Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers |
| Q37015436 | MDR- and CYP3A4-mediated drug-drug interactions |
| Q33981408 | Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males |
| Q24631021 | Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams |
| Q44346900 | Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects |
| Q47909730 | Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC-MS/MS cocktail assays and RT-PCR. |
| Q36909336 | The role of cytochrome P450 in antiretroviral drug interactions |
| Q44874904 | Variability in activity of hepatic CYP3A4 in patients infected with HIV. |
| Q80130962 | [Approach to evaluating the clinical relevance of drug interactions in HIV-infected patients] |
Search more.